Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia-Reference-Cited by-同舟云学术

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

Published:2021-01 Issue: Volume:102 Page:538-543
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Khamis Faryal^ORCID,Al Naabi Hanan,Al Lawati Adil,Ambusaidi Zaiyana,Al Sharji Mariam,Al Barwani Umkulthum,Pandak Nenad,Al Balushi Zakariya,Al Bahrani Maher,Al Salmi Issa,Al-Zakwani Ibrahim^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference38 articles.

1. Favipiravir: a new and emerging antiviral option in COVID-19;Agrawal;Med J Armed Forces India,2020

2. Experimental Treatment with Favipiravir for COVID-19: an Open-Label Control Study [published online ahead of print, 2020 Mar 18];Cai;Engineering (Beijing),2020

3. COVID-UTH Study Group. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series;Doi;Crit Care,2020

4. Discovering drugs to treat coronavirus disease 2019 (COVID-19);Dong;Drug Discov Ther,2020

5. Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir;Fang;Biosafety Health,2020

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Course and Factors Associated With Hospital Admission and Mortality among Sars-Cov 2 Patients within Nairobi Metropolitan Area;2024-05-15

2. Assessment of the efficacy and safety of favipiravir in patients with SARS-CoV-2 infection in United Arab Emirates: A single-center study;PHARM PRACT-GRANADA;2024

3. Favipiravir for treating COVID-19;Cochrane Database of Systematic Reviews;2024-02-05

4. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial;BMC Infectious Diseases;2024-01-15

5. An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic;International Journal of Molecular Sciences;2023-12-26